PALO ALTO, Calif., July 16 /PRNewswire/ -- TOPICA Pharmaceuticals today announced that G. Kirk Raab has been elected chairman of the company’s Board of Directors.
“Greg and I worked together successfully at Genentech and Connetics Corporation, and I look forward to achieving a similar outcome for TOPICA,” said Mr. Raab. “The company is poised for success with its experienced board, management team, significant market potential and novel molecule, luliconazole.”
About Luliconazole
About TOPICA Pharmaceuticals
TOPICA is a privately-held specialty pharmaceutical company focused on licensing, developing and commercializing potent topical prescription products to treat the needs of patients with serious nail and skin conditions. Taking advantage of its established trans-pacific network of scientific and industry contacts, TOPICA has in-licensed its lead product candidate, luliconazole, a topical antifungal agent that is already on the market in Japan. TOPICA is developing luliconazole for the treatment of tinea pedis (athlete’s foot) and onychomycosis (nail and nail bed fungal infections). For more information, please visit http://www.topicapharma.com.
SOURCE TOPICA Pharmaceuticals
CONTACT: Joey Fleury of WeissComm Partners, +1-415-946-1090,
jfleury@wcpglobal.com, for TOPICA Pharmaceuticals
Web site: http://www.topicapharma.com/
